Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CRISPR Therapeutics AG

http://www.crisprtx.com/

Latest From CRISPR Therapeutics AG

Bluebird Files Sickle Cell Gene Therapy, Just Weeks Behind Vertex

The company is seeking a priority review from the US Food and Drug Administration.

Gene Therapy Business Strategies

ICER Says Gene Therapies For Sickle Cell Likely To Improve Lives, But Points To Uncertainties

The drug pricing watchdog said improvement to patients’ quality and length of life from lovo-cel and exa-cel were likely, but noted ongoing uncertainty around durability and toxicity concerns.

Gene Therapy Cost Effectiveness

Vertex/CRISPR Are First To US FDA With A CRISPR Gene-Editing Therapy For Sickle Cell Disease

The companies completed a rolling BLA filing for exagamglogene autotemcel (exa-cel) for sickle cell disease and beta thalassemia, a decade after the discovery of CRISPR.

Gene Therapy Innovation

Investors Take Flight After Bluebird Bio’s Sickle Cell Delay

Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.

Blood & Coagulation Disorders Gene Therapy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • Casebia Therapeutics
UsernamePublicRestriction

Register